Merrimack Pharmaceuticals clinical trials
The registry lists 25 studies whose lead sponsor is Merrimack Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 18, 2018.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 25studies on the registry
- 0open to participants now
What it is testing
The drugs Merrimack Pharmaceuticals’ studies test, most studies first; none is open now — 13 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 8
- 0 open · 4
- 0 open · 4
- 0 open · 3
- gancotamab1 in phase 30 open · 2
- Irinotecan1 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
- Fluorouracil1 in phase 30 open · 1
- 0 open · 1
Show 3 moreShow fewer
- irinotecan sucrosofate1 in phase 30 open · 1
- Leucovorin1 in phase 30 open · 1
- 0 open · 1
All 25 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 711
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 2 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Merrimack Pharmaceuticals.
- Merrimack Pharmaceuticals25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic CancerCompletedNCT02399137Phase 2
- Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedNCT01520389Phase 1
- A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedNCT02538627Phase 1
- A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and StomachTerminatedNCT01774851Phase 2
- Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal CancerWithdrawnNCT02785068Phase 1/2
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTerminatedNCT02213744Phase 2/3
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerStatus unknownNCT01304797Phase 1
- Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid TumorsCompletedNCT01447225Phase 1
- A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersCompletedNCT01209195Phase 1
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersCompletedNCT01451632Phase 1
- Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedNCT00734305Phase 1
- A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00994123Phase 1/2
- A Phase 1 Study of MM-141 in Patients With Advanced Solid TumorsCompletedNCT01733004Phase 1
- Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic CancerCompletedNCT01494506Phase 3
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerCompletedNCT01151046Phase 2
- A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedNCT01447706Phase 2
- A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerCompletedNCT01421472Phase 2
- A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1
- A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive CancersCompletedNCT00911898Phase 1
- MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast CancerCompletedNCT01097460Phase 1
- Phase 2 Study of MM-093 to Treat Patients With UveitisCompletedNCT00444743Phase 2
- Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)CompletedNCT00105976Phase 2
- A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid ArthritisCompletedNCT00458146Phase 2
- Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque PsoriasisCompletedNCT00147329Phase 2